Filing Flows › Immunome (IMNM) › Q2 2025
Immunome (IMNM) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Immunome (IMNM) reported revenue of $4.0M for the second quarter 2025 (Q2 2025), +70% from a year earlier and +37% from the quarter before.
Immunome, Q2 2025: revenue $4.0M (+70% year over year), net loss $43.4M, operating cash flow −$49.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.0M | +37% | +70% |
| Operating profit | −$46.5M | — | — |
| Net earnings | −$43.4M | — | — |
| Operating cash flow | −$49.4M | — | — |
What changed
Revenue was $4.0M in Q2 2025, up 70% year over year and up 37% from the previous quarter.
Operating costs exceeded revenue by $46.5M, an operating margin of -1157.6%. Total costs grew 19% against revenue growth of 70%. The fastest-growing cost line was General & admin (+44%). The quarter ended with a net loss of $43.4M, wider than the previous quarter's $41.6M loss.
Operating cash flow was −$49.4M. Non-cash charges added back $637K of depreciation and amortization and $5.3M of share-based compensation. Working capital and other items used $12.0M. Capital expenditures of $905K exceeded it, leaving free cash flow of −$50.3M.
Questions
What was Immunome's revenue in the second quarter 2025?
Immunome (IMNM) reported revenue of $4.0M for the second quarter 2025 (Q2 2025), +70% from a year earlier and +37% from the quarter before.
Source: Immunome 10-Q on SEC EDGAR.